RxDoctor Payments Data

Robert Chvala, MD

Nephrology · Woodbury, NJNPI 1609814094

Payments from drug & device makers

$612in general payments, 2019–2025

Across 24 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$209
  • Otsuka America Pharmaceutical, Inc.$167
  • Fresenius USA Marketing, Inc.$77
  • Vifor Pharma, Inc.$48
  • Boston Scientific$28
  • Bayer$20
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$55090%
  • Education$6110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$612 in reported general payments places this provider in the 40th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$195,906
Medicare patients
251
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol35$37,625
KerendiaFinerenone19$19,374
Sevelamer Carbonate56$10,147
JardianceEmpagliflozin11$7,576
Clonidine20$3,870
Minoxidil22$1,436
Calcium Acetate23$1,395
Furosemide122$1,366
Bumetanide14$1,210
Losartan Potassium73$982
Potassium Chloride23$966
Metolazone32$931
Lisinopril88$748
Gabapentin12$574
Metoprolol Succinate17$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$209$37,62535 claims
BayerKerendia$20$19,37419 claims
Boehringer IngelheimJardiance$16$7,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →